Abstract
Aim: The Factor V Leiden mutation (G1691A) is a clinically important polymorphism that results in an increased risk of thrombosis. The goal of this study was to compare a temperature gradient capillary electrophoresis (TGCE) platform for the detection of Factor V gene mutations to a conventional restriction fragment length polymorphism (RFLP) assay.
Methods: Three hundred and four samples were analyzed by both TGCE and a common clinical Mnl I/RFLP assay. Concordance of results between the two assays was observed for 302/304 (99.3%) of the samples.
Results: All of the Leiden mutants (23/23, 100%) were identified by TGCE. Of the two discrepant results, one was caused by low peak heights in the TGCE output data and was easily rectified by the addition of a minimum peak height threshold. The second discrepancy resulted from the presence of a G→A transition 95bp downstream of the Leiden mutation site. This polymorphism represents a previously unreported alteration of the Factor V gene.
Conclusions: The TGCE assay is less labor-intensive and has a higher throughput capacity than the Mnl I/RFLP assay. TGCE is a less specific assay than the Mnl I/RFLP assay that allows for the detection of novel polymorphisms, but also creates the need for all positive TGCE results to be confirmed by an alternate method such as sequencing. Our results demonstrate that TGCE is a highly sensitive method for mutation detection and has utility for mutation discovery analysis.
Similar content being viewed by others
Notes
The use of tradenames is for product identification purposes only and does not imply endorsement.
References
Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for Factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504–8
Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation Factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912–7
Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of Factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. Jama 1997; 277: 1305–7
Li Q, Liu Z, Monroe H, et al. Integrated platform for detection of DNA sequence variants using capillary array electrophoresis. Electrophoresis 2002; 23: 1499–511
Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7
Gold B, Hanson M, Dean M. Two rare confounding polymorphisms proximal to the Factor V Leiden mutation. Mol Diagn 2001; 6: 137–40
Ballering LA, Bon MA, Steffens-Nakken HM, et al. Chemiluminescent detection of Factor V Leiden in a routine laboratory. Ann Clin Biochem 1996; 33: 259–62
Barnard R, Futo V, Pecheniuk N, et al. PCR bias toward the wild-type k-ras and p53 sequences: implications for PCR detection of mutations and cancer diagnosis. Biotechniques 1998; 25: 684–91
Ogino S, Wilson RB. Quantification of PCR bias caused by a single nucleotide polymorphism in SMN gene dosage analysis. J Mol Diagn 2002; 4: 185–90
Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the Factor V mutation associated with activated protein C resistance. Thromb Haemost 1995; 74: 874–8
Happich D, Schwaab R, Hanfland P, et al. Allelic discrimination of Factor V Leiden using a 5′ nuclease assay. Thromb Haemost 1999; 82: 1294–6
Neoh SH, Brisco MJ, Firgaira FA, et al. Rapid detection of the Factor V Leiden (1691 G > A) and haemochromatosis (845 G > A) mutation by fluorescence resonance energy transfer (FRET) and real time PCR. J Clin Pathol 1999; 52: 766–9
Ryan D, Nuccie B, Arvan D. Non-PCR-dependent detection of the Factor V Leiden mutation from genomic DNA using a homogeneous invader microtiter plate assay. Mol Diagn 1999; 4: 135–44
Kowalski A, Radu D, Gold B. Colorimetric microwell plate detection of the Factor V Leiden mutation. Clin Chem 2000; 46: 1195–8
Bowen DJ, Standen GR, Granville S, et al. Genetic diagnosis of Factor V Leiden using heteroduplex technology. Thromb Haemost 1997; 77: 119–22
Bowen DJ, Bowley S, John M, et al. Factor V Leiden (G1691A), the prothrombin 3′-untranslated region variant (G20210A) and thermolabile methylenete-trahydrofolate reductase (C677T): a single genetic test genotypes all three loci — determination of frequencies in the S. Wales population of the UK. Thromb Haemost 1998; 79: 949–54
Clark ZE, Bowen DJ, Whatley SD, et al. Genotyping method for methylenete-trahydrofolate reductase (C677T thermolabile variant) using heteroduplex technology. Clin Chem 1998; 44: 2360–2
Barbaux S, Kluijtmans LA, Whitehead AS. Accurate and rapid “multiplex heteroduplexing” method for genotyping key enzymes involved in folate/homocysteine metabolism. Clin Chem 2000; 46: 907–12
Liebman HA, Sutherland D, Bacon R, et al. Evaluation of a tissue Factor dependent Factor V assay to detect Factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance. Br J Haematol 1996; 95: 550–3
Acknowledgements
The authors would like to thank Dr James Eshleman for helpful technical discussions and Lisa Cooper, Tanya Geiger and Patrick Pearson for technical assistance.
No sources of funding were used to assist in conducting this study. The author has no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Murphy, K.M., Hafez, M.J., Philips, J. et al. Evaluation of Temperature Gradient Capillary Electrophoresis for Detection of the Factor V Leiden Mutation. CNS Drugs 7, 35–40 (2003). https://doi.org/10.1007/BF03260018
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03260018